Patents Examined by Kortney L Klinkel
  • Patent number: 11129823
    Abstract: The present disclosure provides a combination of a fused bicyclic amine compound and an anti-inflammatory agent for treating ocular inflammatory disorders and diseases. Further provided are pharmaceutical compositions of the compound and the anti-inflammatory agent.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: September 28, 2021
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young
  • Patent number: 11123346
    Abstract: The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: September 21, 2021
    Assignee: BOW RIVER LLC
    Inventors: Sundar Srinivasan, Christina Chow
  • Patent number: 11116768
    Abstract: This invention applies to the field of medicine, namely to endocrinology, and intended for the treatment of type 1 diabetes mellitus. The invention proposes a combination, containing a Dipeptidyl peptidase-4 (DPP-4) inhibitors, a proton pump inhibitors (PPI), and gamma-aminobutyric acid or a gamma-aminobutyric acid receptor agonists. This unique combination of medications and specific dosage of drugs leads to the regeneration (recovery) of the ?-cells of the pancreas, which is presented by a dramatic reduction of insulin requirements up to a total insulin discontinuation in some persons.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: September 14, 2021
    Assignee: Levicure Ltd.
    Inventor: Shmuel Boris Levit
  • Patent number: 11116721
    Abstract: Novel pharmaceutical formulations of a beta-2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: September 14, 2021
    Assignee: Glaxo Group Limited
    Inventors: Darrell Baker, Mark Bruce, Marian Thomas
  • Patent number: 11110102
    Abstract: The present invention relates to the use of enfumafungin derivative triterpenoid antifungal compounds in combination with other antifungal agents such azoles, polyenes, lipopeptides, and allylamides to treat fungal diseases. More particularly, the invention relates to antifungal combinations of enfumafungin derivative triterpenoids which are inhibitors of (1,3)-?-D-glucan synthesis, in combination with other antifungal agents such as mold-active agents that have activity against molds, including but not limited to voriconazole, isavuconazole, posaconazole, itraconazole and amphotericin B, for the treatment and/or prevention of infections caused by molds.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: September 7, 2021
    Assignee: Scynexis, Inc.
    Inventor: David A. Angulo Gonzalez
  • Patent number: 11103442
    Abstract: A cream to be applied topically to the hair and scalp in order to infuse moisture. The present invention effectuates this capability through a mixture of a raw material blend, in a chemical composition’ proportion that brings about effective results. The prevailing ingredients in the finished product are pumpkin seed oil (Cucurbita pepo), rosehip seed oil (Rosa canina L.), mango butter (Mangifera indica), and citric acid.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: August 31, 2021
    Inventor: Sherrie Liddell
  • Patent number: 11103465
    Abstract: The invention provides a topical pain medication and a method of manufacturing and suing the same. In one embodiment, the medication includes: (1) enriched resveratrol having a concentration of trans-resveratrol therein that substantially exceeds the natural concentrations of trans-resveratrol in naturally occurring resveratrol, and (2) at least one inactive ingredient configured to mix with the resveratrol to form the topical medication. In one embodiment, the method includes: (1) processing resveratrol to increase the concentration of trans-resveratrol therein and (2) mixing at least one inactive ingredient with the resveratrol to form the topical medication.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: August 31, 2021
    Assignee: Ted's Brain Science, Inc.
    Inventors: Dennis I. Robbins, David H. Hitt, Jr., David H. Hitt, III
  • Patent number: 11103499
    Abstract: Compounds of Formula I: or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N-oxides thereof, or a combination thereof, processes and intermediates for preparation thereof, compositions thereof, and uses thereof, are provided. Pharmaceutical compositions comprising a compound of formula I and a compound of Formula II: or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N-oxides thereof, or a combination thereof. Compositions and methods for improving the efficacy of DEX, or providing beneficial pharmacokinetic effects to DEX, comprising co-administering a compound of formula I or SARPO, and a compound of Formula II or DEX to a subject in need thereof, and dosage forms, drug delivery systems, methods of treatment thereof.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: August 31, 2021
    Inventors: Sreenivasarao Vepachedu, Hans J Moebius, Anton Bespalov
  • Patent number: 11096921
    Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: August 24, 2021
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Byung Gyu Kim, Hyun Woo Jeong, Su Kyung Kim, Si Young Cho, Chan Woong Park, Dae Bang Seo, Wan Gi Kim, Sang Jun Lee
  • Patent number: 11096906
    Abstract: The present disclosure relates to a use of a phloroglucinol-based compound and its salt for preventing and treating Alzheimer's disease. The pharmaceutical composition for preventing or treating Alzheimer's disease of the present disclosure fundamentally suppresses the cause of ?-amyloid formation, thereby exerting a remarkable effect of allowing ultimate treatment of Alzheimer's disease. The present disclosure provides the use of the single substance, which has been isolated from Dryopteris crassirhizoma and identified, for preventing or treating Alzheimer's disease for the first time.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: August 24, 2021
    Assignee: SFCBIO. CO., LTD.
    Inventors: So-Young Park, Hwan-Bin Joo
  • Patent number: 11090262
    Abstract: A method of making an oral soluble film, containing at least one active agent, includes providing a well of a predetermined size; depositing a film forming composition in the well; depositing an active agent composition in the well, the active agent composition being different than the film forming composition, the film forming composition and the active agent composition forming an admixture in the well; and drying the admixture in the well. Alternatively, the method includes providing a well of a predetermined size; depositing a film forming composition including at least one active agent in the well, the film forming composition having a viscosity below 2000 centipoise; and drying the film forming composition in the well.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: August 17, 2021
    Assignee: NOVA THIN FILM PHARMACEUTICALS LLC
    Inventors: Richard C. Fuisz, Joseph M. Fuisz
  • Patent number: 11077086
    Abstract: The present invention relates to solid dosage forms of cannabinoid pharmaceutical formulations comprising a solvated cannabinoid for buccal or sublingual administration, and methods of making and using the same.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: August 3, 2021
    Assignee: Pharmaceutical Productions, Inc.
    Inventor: John A. McCarty
  • Patent number: 11072598
    Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: July 27, 2021
    Assignee: CRINETICS PHARMACEUTICALS, INC.
    Inventors: Sangdon Han, Sun Hee Kim, Yunfei Zhu
  • Patent number: 11071736
    Abstract: Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: July 27, 2021
    Inventors: Jiann-Jyh Huang, Shih-Hsien Chuang, Ying-Shuan Eda Lee, Yu-Ling Huang, Johnson Lau
  • Patent number: 11065225
    Abstract: Alzheimer's disease is treated using THC (alone, or in combination with melatonin) administered in an ultra-low dose amount sufficient to (i) reduce Aß expression; (ii) reduce Aß aggregation: (iii) maintain APP expression; (iv) enhance mitochondrial functioning; (v) decrease phosphorylation of GSK3ß protein; (vi) decrease the expression of GSK3ß protein; (vii) decrease phosphorylation of Tau protein; and/or (viii) maintain Tau protein expression, in said patient without severe psychological impairments and side effects associated with higher doses of THC.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: July 20, 2021
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventor: Chuanhai Cao
  • Patent number: 11066400
    Abstract: The present invention relates to a FoxM1 gene splicing modifier selected from a compound of formula (I) or of formula (VI) wherein A and B are as defined herein, or a pharmaceutically acceptable salt thereof, for use in the treatment, prevention and/or delay of progression of cancer.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: July 20, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Friedrich Metzger, Hasane Ratni
  • Patent number: 11058681
    Abstract: A method of treating diarrhea in a patient includes administering an H1 receptor antagonist and an H2 receptor antagonist to the patient.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: July 13, 2021
    Assignee: Maregade RX
    Inventor: Reed B. Hogan
  • Patent number: 11058672
    Abstract: A composition having clevidipine as an active ingredient is described. The composition includes clevidipine as an active ingredient and an amount of the impurity H168/79 that is no greater than about 1.5%, or where the ratio between clevidipine and H168/79 is equal or above 60 to 1.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: July 13, 2021
    Assignee: CHIESI FARMACEUTICA S.P.A.
    Inventors: Rajeshwar Motheram, Gopal Krishna, Min Ding, Keith Flood, Kornepati Ramakrishna
  • Patent number: 11052040
    Abstract: The present invention relates to a composition for boosting immunity in a person comprising a plurality of minerals, a plurality of vitamins, activated charcoal, coffee beans, vitamin B complex and a carrier, wherein the carrier is an oil-based substance. The composition is an aggregation of the active agents/ingredients conventionally prepared. The present invention allows absorption of multiple active agents/ingredients in the body, consistently. The blend of vitamin and minerals get easily absorbed in the body of a patient without affecting the function of the liver.
    Type: Grant
    Filed: March 23, 2019
    Date of Patent: July 6, 2021
    Inventor: Tirent Emanuel Scott
  • Patent number: 11045435
    Abstract: The present invention is related to a method for treating an ocular disease, particularly a diabetes related ocular disease, comprising administering to a subject in need thereof an effective amount of a group of compounds having a structure of Formula A1, wherein the ocular disease is selected from the group consisting of proliferative vitreoretinopathy (PVR), uveitis, glaucoma and age related macular degeneration (AMD), and the diabetes related ocular disease is selected from the group consisting of diabetic retinopathy (DR) and diabetic macular edema (DME).
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: June 29, 2021
    Assignee: NATUREWISE BIOTECH & MEDICALS CORPORATION
    Inventors: George Chung-Yih Chiou, Chia-Nan Chen